JP2017514856A5 - - Google Patents

Download PDF

Info

Publication number
JP2017514856A5
JP2017514856A5 JP2016566651A JP2016566651A JP2017514856A5 JP 2017514856 A5 JP2017514856 A5 JP 2017514856A5 JP 2016566651 A JP2016566651 A JP 2016566651A JP 2016566651 A JP2016566651 A JP 2016566651A JP 2017514856 A5 JP2017514856 A5 JP 2017514856A5
Authority
JP
Japan
Prior art keywords
substituted
alkyl
alkoxy
independently
independently selected
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016566651A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017514856A (ja
JP6483156B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/029409 external-priority patent/WO2015171722A1/en
Publication of JP2017514856A publication Critical patent/JP2017514856A/ja
Publication of JP2017514856A5 publication Critical patent/JP2017514856A5/ja
Application granted granted Critical
Publication of JP6483156B2 publication Critical patent/JP6483156B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016566651A 2014-05-07 2015-05-06 糖尿病などの疾患の治療用のピロリジンgpr40モジュレータ Active JP6483156B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461989651P 2014-05-07 2014-05-07
US61/989,651 2014-05-07
PCT/US2015/029409 WO2015171722A1 (en) 2014-05-07 2015-05-06 Pyrrolidine gpr40 modulators for the treatment of diseases such as diabetes

Publications (3)

Publication Number Publication Date
JP2017514856A JP2017514856A (ja) 2017-06-08
JP2017514856A5 true JP2017514856A5 (enExample) 2018-04-19
JP6483156B2 JP6483156B2 (ja) 2019-03-13

Family

ID=53181359

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016566651A Active JP6483156B2 (ja) 2014-05-07 2015-05-06 糖尿病などの疾患の治療用のピロリジンgpr40モジュレータ

Country Status (33)

Country Link
US (4) US9873679B2 (enExample)
EP (1) EP3140296B1 (enExample)
JP (1) JP6483156B2 (enExample)
KR (1) KR102336370B1 (enExample)
CN (1) CN106458976B (enExample)
AR (1) AR100328A1 (enExample)
AU (1) AU2015256120B2 (enExample)
BR (1) BR112016024936A2 (enExample)
CA (1) CA2948161C (enExample)
CL (1) CL2016002809A1 (enExample)
CY (1) CY1120340T1 (enExample)
DK (1) DK3140296T3 (enExample)
EA (1) EA033250B1 (enExample)
ES (1) ES2674531T3 (enExample)
HR (1) HRP20180641T1 (enExample)
HU (1) HUE039288T2 (enExample)
IL (1) IL248668B (enExample)
MA (1) MA39427B1 (enExample)
MX (1) MX378160B (enExample)
MY (1) MY181959A (enExample)
NZ (1) NZ727146A (enExample)
PE (1) PE20161363A1 (enExample)
PH (1) PH12016502034B1 (enExample)
PL (1) PL3140296T3 (enExample)
PT (1) PT3140296T (enExample)
RS (1) RS57170B1 (enExample)
SG (1) SG11201609170UA (enExample)
SI (1) SI3140296T1 (enExample)
SM (1) SMT201800342T1 (enExample)
TN (1) TN2016000444A1 (enExample)
TR (1) TR201809633T4 (enExample)
TW (1) TWI659951B (enExample)
WO (1) WO2015171722A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2015256038B2 (en) * 2014-05-07 2019-07-11 Bristol-Myers Squibb Company Pyrrolidine GPR40 modulators for the treatment of diseases such as diabetes
MA39427B1 (fr) * 2014-05-07 2018-09-28 Bristol Myers Squibb Co Composés pyrrolidine modulateurs de gpr40 pour le traitement de maladies telles que le diabète
JP7086942B2 (ja) 2016-09-12 2022-06-20 インテグラル ヘルス, インコーポレイテッド Gpr120モジュレーターとして有用な単環式化合物
CN110121343B (zh) 2016-09-12 2023-11-03 整体健康 用作gpr120调节剂的双环化合物
US11186565B2 (en) 2017-03-31 2021-11-30 Takeda Pharmaceutical Company Limited Aromatic compound
CN110538327B (zh) * 2017-08-21 2021-08-03 武汉大学 Gpr31抑制剂在制备治疗脂肪代谢异常及相关疾病的药物中的应用
EP4227302A1 (en) 2018-02-13 2023-08-16 Gilead Sciences, Inc. Pd-1/pd-l1 inhibitors
US10899735B2 (en) 2018-04-19 2021-01-26 Gilead Sciences, Inc. PD-1/PD-L1 inhibitors
UA126421C2 (uk) 2018-07-13 2022-09-28 Гіліад Сайєнсіз, Інк. Інгібітори pd-1/pd-l1
AU2019366355B2 (en) 2018-10-24 2022-10-13 Gilead Sciences, Inc. PD-1/PD-L1 inhibitors
AU2019387370A1 (en) 2018-11-30 2021-06-10 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof
AU2022291768A1 (en) 2021-06-16 2023-11-30 Celgene Corporation Azetidinyl compounds comprising a carboxylic acid group for the treatment of neurodegenerative diseases
CN116283699B (zh) * 2023-03-02 2025-02-11 遵义医科大学 一种合成氟烷基取代的吡咯烷的方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5614492A (en) 1986-05-05 1997-03-25 The General Hospital Corporation Insulinotropic hormone GLP-1 (7-36) and uses thereof
WO2011044073A1 (en) * 2009-10-06 2011-04-14 Bristol-Myers Squibb Company Pyrrolidine gpr40 modulators
US7939569B1 (en) * 2009-12-01 2011-05-10 Hoffmann-La Roche Inc. Aniline analogs as glycogen synthase activators
GB2498976A (en) * 2012-02-01 2013-08-07 Prosidion Ltd GPR119 agonists useful in the treatment of type II diabetes
US9120798B2 (en) 2012-08-01 2015-09-01 Bristol-Myers Squibb Company Amino-heteroaryl 7-hydroxy-spiropiperidine indolinyl antagonists of P2Y1 receptor
CN104812748B (zh) * 2012-11-16 2017-10-24 百时美施贵宝公司 二氢吡唑gpr40调节剂
SG11201503556PA (en) 2012-11-16 2015-06-29 Bristol Myers Squibb Co Dihydropyrazole gpr40 modulators
KR20150082615A (ko) * 2012-11-16 2015-07-15 브리스톨-마이어스 스큅 컴퍼니 피롤리딘 gpr40 조절제
MX2015005720A (es) 2012-11-16 2015-09-08 Bristol Myers Squibb Co Moduladores de dihidropirazol de receptor acoplado a la proteina g (gpr40).
WO2015171757A1 (en) 2014-05-07 2015-11-12 Bristol-Myers Squibb Company Pyrrolidine gpr40 modulators
MA39427B1 (fr) * 2014-05-07 2018-09-28 Bristol Myers Squibb Co Composés pyrrolidine modulateurs de gpr40 pour le traitement de maladies telles que le diabète
HRP20191667T1 (hr) 2014-05-07 2019-12-13 Croma Pharma Ges M B H Vodenasta oftalmološka otopina i postupak tretmana sindroma suhog oka

Similar Documents

Publication Publication Date Title
JP2017514856A5 (enExample)
JP7664947B2 (ja) Il-17の調節因子としてのイミダゾリダジン
JP6130964B2 (ja) Apj受容体のトリアゾールアゴニスト
JP7611278B2 (ja) 金属酵素阻害剤化合物
JP2018505203A5 (enExample)
JP2017508794A5 (enExample)
JP2016516043A5 (enExample)
JP5487202B2 (ja) 新規甲状腺ホルモンβ受容体作動薬
JP2024514010A (ja) カルボキシ-ベンズイミダゾールglp-1r調節化合物
JP2016520128A5 (enExample)
JP2015500887A5 (enExample)
RU2016115803A (ru) Замещенные никотинимидные ингибиторы втк, их получение и применение в терапии раковых, воспалительных и аутоиммунных заболеваний
JP2017508795A5 (enExample)
JP2017529389A5 (enExample)
RU2011121567A (ru) Изоиндолиновые соединения для применения при лечении рака
JP2016526576A5 (enExample)
CA2903288A1 (en) N-acyl-n'-(pyridin-2-yl) ureas and analogs exhibiting anti-cancer and anti-proliferative activities
JP2016525136A5 (enExample)
JP2013518110A (ja) 疼痛および他の適応症の治療用の医薬組成物
JP2016513696A5 (enExample)
CN105085428B (zh) 芳杂环类衍生物及其在药物上的应用
JP2021512114A5 (enExample)
CN112955448A (zh) 芳环或芳杂环类化合物及其制备方法和医药用途
JP2018534288A5 (enExample)
JP2016513681A5 (enExample)